GUJTHEM NSE filing

Reminder: Special window for re-lodgement of physical share transfer requests

The RealCase readLow impact Neutral

Gujarat Themis Biosyn Limited reminds shareholders about the special window for re-lodgement of transfer requests for physical shares open until 6 January 2026.

Why it matters

The announcement is a routine reminder and is unlikely to have a significant impact on the company's stock or operations.

The market read

The announcement is a reiteration of a previously announced facility and does not contain any positive or negative information.

* Gujarat Themis Biosyn Limited reminds shareholders about the special window for re-lodgement of transfer requests for physical shares, which is open until 6 January 2026. * This facility applies to cases where original share transfer requests before 1 April 2019 were rejected or remained unattended due to deficiencies. * Re-lodged requests will be processed only in dematerialized form, subject to document verification. * Shareholders can submit requests to the Company's Registrar and Share Transfer Agent (RTA) at MUFG Intime India Private Limited in Mumbai.

Filing to action

What to do with a filing like this

Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under share transfer updates. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.

View original filing